232 related articles for article (PubMed ID: 25770290)
1. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.
Rodrigues LU; Rider L; Nieto C; Romero L; Karimpour-Fard A; Loda M; Lucia MS; Wu M; Shi L; Cimic A; Sirintrapun SJ; Nolley R; Pac C; Chen H; Peehl DM; Xu J; Liu W; Costello JC; Cramer SD
Cancer Res; 2015 Mar; 75(6):1021-34. PubMed ID: 25770290
[TBL] [Abstract][Full Text] [Related]
2.
Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
[TBL] [Abstract][Full Text] [Related]
3. Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Ormond DR; Kleinschmidt-DeMasters BK; Cavalcante D; Smith EE; Cramer SD; Lucia MS
J Neurooncol; 2019 Apr; 142(2):319-325. PubMed ID: 30656528
[TBL] [Abstract][Full Text] [Related]
4. Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination.
Washino S; Rider LC; Romero L; Jillson LK; Affandi T; Ohm AM; Lam ET; Reyland ME; Costello JC; Cramer SD
Mol Cancer Res; 2019 Oct; 17(10):1985-1998. PubMed ID: 31300540
[TBL] [Abstract][Full Text] [Related]
5. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
6. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
7. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
[No Abstract] [Full Text] [Related]
8.
Bayne RS; Puckett S; Rodrigues LU; Cramer SD; Lee J; Furdui CM; Chou JW; Miller LD; Ornelles DA; Lyles DS
Mol Ther Oncolytics; 2020 Jun; 17():496-507. PubMed ID: 32529027
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.
Liu W; Lindberg J; Sui G; Luo J; Egevad L; Li T; Xie C; Wan M; Kim ST; Wang Z; Turner AR; Zhang Z; Feng J; Yan Y; Sun J; Bova GS; Ewing CM; Yan G; Gielzak M; Cramer SD; Vessella RL; Zheng SL; Grönberg H; Isaacs WB; Xu J
Oncogene; 2012 Aug; 31(35):3939-48. PubMed ID: 22139082
[TBL] [Abstract][Full Text] [Related]
10. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Tak1 promotes prostate tumorigenesis.
Wu M; Shi L; Cimic A; Romero L; Sui G; Lees CJ; Cline JM; Seals DF; Sirintrapun JS; McCoy TP; Liu W; Kim JW; Hawkins GA; Peehl DM; Xu J; Cramer SD
Cancer Res; 2012 Jun; 72(11):2833-43. PubMed ID: 22467172
[TBL] [Abstract][Full Text] [Related]
12. MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression.
Huang Z; Tang B; Yang Y; Yang Z; Shi L; Bai Y; Yan B; Karnes RJ; Zhang J; Jimenez R; Wang L; Wei Q; Yang J; Xu W; Jia Z; Huang H
Cancer Res; 2021 Sep; 81(17):4471-4484. PubMed ID: 34158377
[TBL] [Abstract][Full Text] [Related]
13. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
14. CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo.
Oh-Hohenhorst SJ; Tilki D; Ahlers AK; Suling A; Hahn O; Tennstedt P; Matuszcak C; Maar H; Labitzky V; Hanika S; Starzonek S; Baumgart S; Johnsen SA; Kluth M; Sirma H; Simon R; Sauter G; Huland H; Schumacher U; Lange T
Cancer Gene Ther; 2022 Jan; 29(1):49-61. PubMed ID: 33414516
[TBL] [Abstract][Full Text] [Related]
15. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
16. CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.
Li H; Wang Y; Lin K; Venkadakrishnan VB; Bakht M; Shi W; Meng C; Zhang J; Tremble K; Liang X; Song JH; Feng X; Van V; Deng P; Burks JK; Aparicio A; Keyomarsi K; Chen J; Lu Y; Beltran H; Zhao D
Cancer Res; 2022 Sep; 82(17):3088-3101. PubMed ID: 35771632
[TBL] [Abstract][Full Text] [Related]
17. Relationship between LSD1 expression and E-cadherin expression in prostate cancer.
Wang M; Liu X; Jiang G; Chen H; Guo J; Weng X
Int Urol Nephrol; 2015 Mar; 47(3):485-90. PubMed ID: 25627913
[TBL] [Abstract][Full Text] [Related]
18. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]